The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the signaling of interleukin (IL)-31.
Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...
Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback